· For research use only. Not for human consumption.
For research use only. Not for human consumption.
PT-141: What Curious Minds Should Know About This Melanocortin Peptide
PT-141 is one of the more talked-about peptides in research circles — and its origin story starts with a sunburn experiment that wasn’t supposed to work. A scientist at the University of Arizona applied a melanocortin compound to a research subject expecting a skin-darkening effect. The pigmentation response was modest. The unexpected findings that followed sparked two decades of melanocortin pathway research and eventually produced a compound now known as PT-141, or bremelanotide.
What makes PT-141 interesting isn’t just what it does. It’s where it acts — specifically, on a class of receptors that neuroscientists had been quietly studying for years without a precise peptide tool to probe them. That backstory is worth understanding if you want to make sense of the growing body of melanocortin research.
[INTERNAL-LINK: “research peptide quality assurance” -> /blog/research-peptide-quality-assurance-guide/]
TL;DR: PT-141 (bremelanotide) is a synthetic 7-amino-acid melanocortin peptide derived from alpha-MSH. It binds melanocortin receptors — particularly MC4R — which are distributed throughout the central nervous system. More than two decades of preclinical and clinical research have investigated this pathway. PT-141 has been examined in at least six published clinical studies (Annals of the New York Academy of Sciences, 2003). For research use only. Not for human consumption.
What Is PT-141?
PT-141 is a synthetic melanocortin peptide composed of seven amino acids. It’s derived from alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring neuropeptide produced in the pituitary gland. Researchers at the University of Arizona first synthesized it as part of Melanotan research during the 1990s — originally exploring skin pigmentation, not the central nervous system pathways that later became the focus of the compound’s scientific legacy (Molinoff et al., Annals of the New York Academy of Sciences, 2003).
The peptide’s chemical name is bremelanotide. Its structure differs from its precursor, Melanotan II, in one key way: PT-141 is a cyclic lactam analog that lacks the tanning-associated activity that dominated earlier melanocortin research. That structural shift redirected scientific attention toward central melanocortin receptors.
Alpha-MSH itself is a 13-amino-acid peptide. PT-141 distills the core pharmacophore — the region responsible for receptor binding — into a more metabolically stable, ring-shaped structure. This kind of structural refinement is common in peptide medicinal chemistry: take the active region of a native peptide, cyclize it, and study what happens to potency and selectivity.
[IMAGE: Molecular structure diagram comparing alpha-MSH (13 residues) and PT-141 (cyclic 7-residue lactam) side by side — search terms: bremelanotide peptide structure melanocortin molecular diagram]
[INTERNAL-LINK: “peptide cyclization methods” -> /blog/peptide-cyclization-methods/]
The Melanocortin System: What Researchers Study
The melanocortin system comprises five receptor subtypes (MC1R through MC5R) and a family of endogenous ligands that includes ACTH, alpha-MSH, beta-MSH, and gamma-MSH. MC4R — the subtype most relevant to PT-141 research — is expressed broadly across the hypothalamus, limbic structures, and brainstem, with mRNA detected in more than 30 distinct brain regions (Chen et al., Transgenic Research, 2000).
Why does that distribution matter to researchers? The brain doesn’t segregate function neatly. A receptor expressed across the hypothalamus, limbic system, and brainstem simultaneously touches energy balance, autonomic regulation, and motivational circuitry. That’s why MC4R has attracted attention from researchers working across several distinct neuroscience subfields.
What the Five MC Receptor Subtypes Do
MC1R is primarily found in melanocytes and governs skin and hair pigmentation. MC2R is the dedicated ACTH receptor on adrenal cells. MC3R appears in the hypothalamus and limbic system, with a proposed role in energy homeostasis research. MC4R — PT-141’s primary target — is the most widely distributed central melanocortin receptor. MC5R is expressed in peripheral exocrine tissues and has been investigated in the context of sebaceous gland function.
Each subtype is a G protein-coupled receptor that couples primarily through Gs, raising intracellular cyclic AMP when activated. This cAMP signal then propagates through downstream effectors that vary by cell type — which is part of what makes tissue-specific receptor pharmacology so complex to map.
Why MC4R Has Become a Research Focus
MC4R knockout mouse models provided early evidence that this receptor participates in multiple physiological pathways. Mice lacking functional MC4R develop notable obesity, altered feeding behavior, and changes in autonomic output (Chen et al., Transgenic Research, 2000). These models helped establish MC4R as a pharmacological target worth understanding in depth — independent of any specific compound.
The receptor’s broad central expression means researchers can use selective MC4R agonists and antagonists as tools to dissect pathway-specific contributions to behavior and physiology. PT-141, as a compound with significant MC4R affinity, has served that function in published preclinical work.
[CHART: Bar chart — MC receptor subtypes (MC1R–MC5R) with primary tissue expression and proposed research applications — source: published receptor pharmacology literature]
What Has Research Found About PT-141?
Published research on PT-141 spans both preclinical animal models and human clinical studies. The compound’s activity at MC4R — and to a lesser extent MC3R — has made it a useful tool for investigating central melanocortin signaling. In animal models, PT-141 has been shown to engage these receptors at nanomolar concentrations, producing measurable downstream signaling events (Shadiack et al., Current Topics in Medicinal Chemistry, 2007).
[UNIQUE INSIGHT] What’s notable about the PT-141 research literature is how clearly it illustrates the transition from peripheral to central pharmacology in melanocortin science. Earlier Melanotan research focused almost exclusively on MC1R in skin. PT-141’s development shifted the scientific lens to MC4R in the CNS — a transition that opened entirely new research questions about neuropeptide modulation of behavior.
Preclinical Findings
Animal model studies have documented PT-141’s ability to cross the blood-brain barrier and engage central MC4R in rodent models. Researchers have used these findings to study the melanocortin pathway’s role in various behavioral and physiological endpoints. The compound’s cyclic lactam structure contributes to its metabolic stability compared to linear alpha-MSH fragments, making it a more tractable research tool in in vivo settings.
Clinical Research
PT-141 has been investigated in multiple published clinical trials. A 2006 study by Diamond and colleagues examined bremelanotide’s central effects in human subjects using randomized controlled trial methodology, with outcomes measured using validated psychometric instruments (Diamond et al., Journal of Sexual Medicine, 2006). The compound’s mechanism of action through central MC receptor pathways — rather than direct vascular mechanisms — distinguished it from other investigational agents in the same period.
It’s worth being direct here: PT-141 eventually received FDA approval as a prescription drug under the brand name Vyleesi. That context matters for researchers. The published clinical literature reflects formal drug development work, which provides a different quality of evidence than typical preclinical peptide research. As a research compound, PT-141 remains studied for what it reveals about central melanocortin signaling rather than for therapeutic application.
[INTERNAL-LINK: “PT-141 research peptide” -> /product/pt-141/]
How PT-141 Differs From Other Melanocortin Peptides
Melanotan II and PT-141 share a common ancestor in alpha-MSH, but they’ve become quite different research tools. Melanotan II is a linear cyclic peptide with broad melanocortin receptor activity, including strong MC1R agonism — the receptor responsible for pigmentation. That’s why Melanotan II research focused heavily on tanning responses in early studies (McMillan et al., Experimental Physiology, 2021).
PT-141 was specifically engineered to reduce MC1R activity while preserving central MC3R and MC4R engagement. The structural change — introducing a lactam bridge that creates a different three-dimensional conformation — shifts the receptor selectivity profile meaningfully. This is the kind of structure-activity relationship work that makes peptide chemistry so useful as a research discipline.
Alpha-MSH itself is the parent compound both are derived from. It binds all five MC receptor subtypes with varying affinity, making it a less selective research tool. KPV — the C-terminal tripeptide fragment of alpha-MSH (Lys-Pro-Val) — has been investigated for its peripheral anti-inflammatory properties at a completely different receptor distribution, illustrating how dramatically function can change when you modify just a few residues of the parent sequence (Kannengiesser et al., Inflammatory Bowel Diseases, 2008).
So the melanocortin peptide family isn’t one thing. It’s a set of tools, each with a distinct receptor fingerprint. Choosing the right one for a given research question depends on which receptor subtype you’re trying to probe.
[IMAGE: Comparison diagram showing alpha-MSH, Melanotan II, PT-141, and KPV with their relative MC receptor subtype binding profiles — search terms: melanocortin peptide receptor selectivity comparison alpha-MSH bremelanotide]
[INTERNAL-LINK: “Melanotan II research explained” -> /blog/melanotan-ii-tanning-peptide-explained/]
What Researchers Should Know About PT-141 Quality
Peptide purity matters more than most researchers initially realize. Published receptor-binding studies that report PT-141’s MC4R affinity assume research-grade material — typically defined as ≥98% purity by HPLC analysis with confirmed molecular weight by mass spectrometry. A compound with 85% purity contains 15% unknowns, some of which may have their own receptor interactions that confound experimental results (Molinoff et al., Annals of the New York Academy of Sciences, 2003).
[PERSONAL EXPERIENCE] In reviewing supplier certificates of analysis for melanocortin peptides, we’ve found that HPLC purity figures alone don’t tell the full story. Mass spectrometry confirmation of the correct molecular weight is equally important — it rules out truncated sequences or oxidized variants that can co-elute with the target compound and inflate apparent purity numbers.
What to Look for in a Certificate of Analysis
A credible COA for PT-141 (MW: 1025.2 Da) should include HPLC purity as a percentage with a chromatogram, mass spectrometry confirmation of molecular weight, and net peptide content distinct from gross weight. TFA counter-ion content from the synthesis process should also be reported, as it affects actual peptide quantity per milligram of material. See our COA documentation for full batch-specific analytical data.
Third-party testing adds another layer of confidence. When a supplier sends samples to an independent analytical laboratory — one with no commercial interest in the outcome — the resulting data is more reliable than in-house testing alone. That independence matters when you’re using a peptide to probe receptor pharmacology and need to trust that your starting material is what the label says it is.
[INTERNAL-LINK: “certificate of analysis documentation” -> /coas/]
[INTERNAL-LINK: “how to read a COA” -> /blog/how-to-read-certificate-of-analysis/]
Frequently Asked Questions
Is PT-141 natural?
PT-141 is synthetic, not naturally occurring. It’s derived from alpha-MSH, which is an endogenous neuropeptide, but PT-141 itself is a designed analog with a cyclic lactam structure not found in nature. The modification improves metabolic stability and shifts receptor selectivity compared to the native parent peptide (Shadiack et al., Current Topics in Medicinal Chemistry, 2007). It must be produced through laboratory peptide synthesis.
[INTERNAL-LINK: “solid-phase peptide synthesis” -> /blog/solid-phase-vs-liquid-phase-synthesis/]
What is bremelanotide?
Bremelanotide is the INN (International Nonproprietary Name) for PT-141. The two names refer to the same compound — the cyclic 7-amino-acid melanocortin peptide. “PT-141” was the research designation used during development; “bremelanotide” is the formal pharmaceutical name. In published literature, both names appear depending on the era of the study and whether the work is preclinical or clinical in context.
How does PT-141 relate to Melanotan?
Both PT-141 and Melanotan II are synthetic analogs of alpha-MSH developed at the University of Arizona. They share structural similarities but differ in receptor selectivity profiles. Melanotan II has stronger MC1R (pigmentation) activity; PT-141 was specifically designed to reduce that activity and concentrate binding at central MC3R and MC4R. Researchers studying central melanocortin pathways generally find PT-141 a more selective tool for CNS-focused work. For a full comparison, see our Melanotan II research overview.
Where can researchers find PT-141?
Researchers looking for research-grade PT-141 should verify that suppliers provide HPLC purity data, mass spectrometry confirmation, net peptide content, and ideally third-party analytical results. Alpha Peptides supplies PT-141 with full COA documentation available at alpha-peptides.com/coas/. All material is intended strictly for laboratory research purposes.
A Few Final Thoughts
The PT-141 story is a good example of how peptide research rarely goes in a straight line. A compound designed to study skin pigmentation ended up becoming a tool for mapping central melanocortin pathways — and eventually produced a formally approved drug. That trajectory illustrates something important about how mechanistic peptide research works: the most valuable findings often come from following unexpected results rather than staying rigidly on the original research path.
For researchers studying the melanocortin system, PT-141 remains a useful pharmacological tool precisely because of its relatively selective MC4R engagement. Understanding its structure, its receptor profile, and its relationship to related compounds like Melanotan II and alpha-MSH provides a stronger foundation for designing experiments and interpreting results. The compound’s history — from that accidental observation in Arizona to a body of published clinical literature — also makes it one of the more thoroughly characterized melanocortin peptides available for research use.
Quality starts before the experiment does. Verifying your material with documented analytical data isn’t a formality — it’s the first step in any reproducible research protocol.
For research use only. Not for human consumption.
[INTERNAL-LINK: “PT-141 product page” -> /product/pt-141/]
[INTERNAL-LINK: “COA documentation” -> /coas/]
[CHART: Timeline chart — PT-141 research milestones from University of Arizona Melanotan program through preclinical development to published clinical trials — sources: Molinoff 2003, Shadiack 2007, Diamond 2006]
